Ticker Details
PTC Therapeutics, Inc. PTC Therapeutics Inc is a biopharmaceutical company. It is focused on the discovery and development of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes.
IPO Date:	June 20, 2013
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$5.83B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.97 | 2.84%
Avg Daily Range (30 D):	$1.45 | 1.88%
Avg Daily Range (90 D):	$1.43 | 1.92%

Institutional Daily Volume
Avg Daily Volume:	.74M
Avg Daily Volume (30 D):	.85M
Avg Daily Volume (90 D):	1.15M

Trade Size
Avg Trade Size (Sh.):	85
Avg Trade Size (Sh.) (30 D):	45
Avg Trade Size (Sh.) (90 D):	59

Institutional Trades
Total Institutional Trades:	8,434
Avg Institutional Trade:	$3.14M
Avg Institutional Trade (30 D):	$5.85M
Avg Institutional Trade (90 D):	$6.46M
Avg Institutional Trade Volume:	.07M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$5.59M
Avg Closing Trade (30 D):	$19.06M
Avg Closing Trade (90 D):	$23.29M
Avg Closing Volume:	119.82K

News

Jul 13, 2026 @ 11:28 PM What This PTC Therapeutics Insider Sale Means as P... Source: Jonathan Ponciano

Dec 31, 2025 @ 3:47 PM What's Going On With Royalty Pharma Stock Wednesda... Source: Vandana Singh

Dec 29, 2025 @ 9:40 PM Royalty Pharma Acquires Remaining Royalty Interest... Source: Globe Newswire

Sep 5, 2025 @ 12:35 PM Here's Why Shares in PTC Therapeutics Soared This ... Source: Lee Samaha

Jul 17, 2025 @ 5:00 AM Novartis reports strong Q2 with double-digit sales... Source: Novartis

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-.64	$1.01	$-.03
Diluted EPS	$-.58	$.92	$-.03
Revenue	$1.01B	$360.52M	$272.55M
Gross Profit
Net Income / Loss	$-38.38M	$83.5M	$-2.81M
Operating Income / Loss	$125.6M	$148.98M	$44.96M
Cost of Revenue
Net Cash Flow	$33.59M	$218.44M	$-146.38M
PE Ratio